[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628713":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-4324","EXPERIMENTAL","Participants will be administered a single dose of ALN-4324.",[13],"Drug: ALN-4324",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ALN-4324 will be administered subcutaneously (SC).",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo will be administered SC.",[15],[30],{"name":31,"affiliation":5,"role":32},"Medical Director","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":35,"role":36,"phone":40,"phoneExt":25,"email":38},"1-877-256-9526",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":25},"Clinical Trial Site","RECRUITING","Chula Vista","California","91911","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-117.0842,32.64005,{"lat":54,"lon":53},{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100628713","phase-2-a-study-to-evaluate-aln-4324-on-insulin-sensitivity-in-adults-with-type-2-diabetes-mellitus-100628713",false,"NCT07465224","A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus","A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Is an adult patient with a confirmed diagnosis of T2DM\n* Has a body mass index (BMI) of ≥25 kg\u002Fm\\^2 and \\\u003C39.9 kg\u002Fm\\^2\n* Has a hemoglobin A1c (HbA1c) ≥6.5% to \\\u003C10.5%\n* Is on a stable dose of metformin\n\nExclusion Criteria:\n\n* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results\n* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods\n\nNote: other protocol defined inclusion\u002Fexclusion criteria apply","ALL","18 Years","65 Years",{"count":69,"type":70},40,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM",[76],"Type 2 Diabetes Mellitus (T2DM)",[78,79],"siRNA","RNAi","2026-06-10",{"date":82,"type":83},"2026-06-12","ACTUAL",{"date":85,"type":83},"2026-01-15",{"date":87,"type":70},"2027-05-28",{"name":5,"class":6},1]